1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
J2KBIO Co., Ltd.

J2KBIO Co., Ltd.

KKRX:420570
8,530.00
KRW
+120.00
(+1.43%)
994.28EPS
7.53P/E
43.80BMarket Cap
J2KBIO Co., Ltd.
KRX:420570
(Korea Stock Exchange)

Recent

price

8,530.00

P/E

ratio

7.53

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
KRW
228,352.77
224,033.85
229,869.24
3,442.67
5,883.88
5,994.02
5,661.23
7,507.61
Revenue per Share
38,500.71
23,853.93
26,240.99
448
1,001
-299
459
994.28
Basic EPS, GAAP
-35,380.26
-18,809.28
18,589.83
272.18
350.98
-17.47
162.1
606.2
Free Cash Flow per Basic Share
- -
- -
- -
- -
49.64
- -
196.9
- -
Dividend per Share
1,145.58
1,438.23
1,758.63
2,151.47
3,532.89
5,467.4
5,775.41
6,254.08
Book Value per Share
1,143.93
1,408.57
1,725.43
2,112.64
3,455.19
5,394.64
5,698.28
6,177.4
Tangible Book Value per Share
- -
- -
- -
5
5
6
6
6
Basic Weighted Avg Shares
13,772
13,858
14,219
16,032
28,472
33,129
32,966
43,899
Sales/Revenue/Turnover
17.51
8.13
13.18
14.5
19.69
10.95
8.86
14.8
Operating Margin (%)
63
334
507
557
634
1,118
1,500
918
Depreciation Expense
2,322
1,475
1,623
2,086
4,844
-1,653
2,673
5,814
Net Income, GAAP
15.54
0.04
- -
5.44
13.89
- -
12.14
16.96
Effective Tax Rate (%)
16.86
10.65
11.42
13.01
17.01
-4.99
8.11
13.24
Profit Margin (%)
4,331
4,204
5,745
7,323
10,204
17,287
18,848
17,971
Working Capital
3,719
3,918
3,045
2,253
527
1,848
852
715
LT Debt
5,776
7,251
8,933
10,892
17,811
31,344
33,772
36,571
Total Equity
- -
10.11
- -
16.47
29.02
- -
7.53
15.17
Return on Invested Capital (%)
- -
14.38
- -
17.21
30.27
- -
7.94
16.5
Return on Capital (%)
- -
22.65
20.14
21.17
33.8
-6.72
8.21
16.91
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
283
278
275
LT Borrowings
400
400
400
LT Finance Leases
452
382
315
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
50,288
44,616
43,798

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
21,944
22,505
23,742
Cash, Cash Equivalents & STI
12,701
9,326
9,854
Accounts Receivable, Net
5,401
7,798
8,243
Inventories
3,273
3,832
4,436
Total Current Liabilities
3,095
6,016
5,771
Payables & Accruals
- -
- -
- -
ST Debt
283
278
275
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.48%
7.75%
Free Cash Flow
- -
-267.53%
-1,077.37%
Net Income, GAAP
- -
-45.03%
-261.74%
Sales/Revenue/Turnover
- -
21.76%
-0.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,809
12,043
6,513
6,764
33,129
2025
7,268
8,529
8,563
8,606
32,966
2026
11,126
15,605
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-834
470
-45
50.43
-299
2025
41
151
143.37
122.21
459
2026
272.72
456
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
196.9
2026
- -
- -
- -
- -
- -
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
Aether Industries Ltd. (NSE:AETHER)
AARTI Industries Ltd (NSE:AARTIIND)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
J2KBIO Co., Ltd. is a South Korea-based biotechnology company primarily engaged in the research, development, and commercial manufacturing of bio-active ingredients and functional raw materials for the cosmetics, personal care, and derma-skincare industries. The company utilizes proprietary microorganism strain libraries, bioconversion, and advanced extraction technologies to provide an extensive product portfolio categorized into bio-fermented materials, including skin microbiome-derived active compounds, proprietary Metabiome substances, and fermented plant extracts designed for skin regeneration and anti-aging; natural botanical extracts, encompassing high-purity plant-derived active ingredients for skin brightening, soothing, moisturizing, and barrier enhancement; functional and synthetic active materials, such as targeted anti-inflammatory agents, antioxidant complexes, and UV-damage protection compounds; and customized biotechnology services, comprising custom ingredient synthesis, strain separation, extraction optimization, and OEM/ODM raw material development. J2KBIO serves leading domestic and global cosmetics manufacturers, original design manufacturers (ODMs), and brand conglomerates, including Cosmax, Kolmar Korea, and Cosmecca Korea, with geographic reach spanning South Korea, Asia-Pacific, North America, and Europe. In recent operational developments, J2KBIO completed its public listing on the KOSDAQ market through a business combination with Kyobo 11th Special Purpose Acquisition Company (SPAC) in 2024. Following the listing, the company has expanded its manufacturing capacity and technological capabilities through the establishment of an automated smart manufacturing facility and advanced bio-fermentation research center in Cheongju, launched next-generation skin-microbiome and exosome-based cosmetic active ingredient lines, and broadened international supply partnerships to support the global expansion of indie and prestige skincare brands. Founded in 2017, J2KBIO Co., Ltd. is headquartered in Cheongju-si, Chungcheongbuk-do, South Korea.